NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free AMRN Stock Alerts $0.91 -0.01 (-1.09%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.89▼$0.9350-Day Range$0.82▼$1.3552-Week Range$0.65▼$1.49Volume464,012 shsAverage Volume995,057 shsMarket Capitalization$373.71 millionP/E RatioN/ADividend YieldN/APrice Target$1.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Amarin alerts: Email Address Amarin MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside19.0% Upside$1.08 Price TargetShort InterestHealthy3.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.14) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector4945th out of 5,424 stocksPharmaceutical Preparations Industry2353rd out of 2,550 stocks 1.9 Analyst's Opinion Consensus RatingAmarin has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.Amount of Analyst CoverageAmarin has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.86% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Amarin has recently decreased by 12.10%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRN. Previous Next 2.3 News and Social Media Coverage News SentimentAmarin has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Amarin this week, compared to 2 articles on an average week.Search Interest10 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.14) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -7.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -7.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Amarin Stock (NASDAQ:AMRN)Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More AMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRN Stock News HeadlinesMay 4, 2024 | americanbankingnews.comQ2 2025 EPS Estimates for Amarin Co. plc Lowered by Zacks Research (NASDAQ:AMRN)May 3, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call TranscriptMay 4, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 2, 2024 | finance.yahoo.comAmarin First Quarter 2024 Earnings: EPS Beats ExpectationsMay 1, 2024 | markets.businessinsider.comAmarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European GrowthMay 1, 2024 | finance.yahoo.comAmarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic FocusMay 1, 2024 | fool.comAmarin Plc (AMRN) Q1 2024 Earnings Call TranscriptMay 1, 2024 | investorplace.comAMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024May 4, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 1, 2024 | globenewswire.comAmarin Reports First Quarter 2024 Business Update and Financial ResultsApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from Amarin's earnings reportApril 30, 2024 | msn.comAmarin Q1 2024 Earnings PreviewApril 24, 2024 | finance.yahoo.comAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventApril 24, 2024 | globenewswire.comAmarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventApril 24, 2024 | americanbankingnews.comAmarin (AMRN) to Release Earnings on WednesdayApril 22, 2024 | globenewswire.comAmarin Announces Results of Annual General Meeting of ShareholdersApril 18, 2024 | seekingalpha.comAmarin Corporation: Small Signs Of Recovery May Not Be EnoughApril 15, 2024 | globenewswire.comAmarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024April 8, 2024 | finanznachrichten.deAmarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsApril 8, 2024 | globenewswire.comAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24April 6, 2024 | globenewswire.comNew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsApril 3, 2024 | fool.comWhy Amarin Stock Was Rocketing Higher on WednesdayApril 3, 2024 | markets.businessinsider.comAmarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick FactsApril 3, 2024 | globenewswire.comAmarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeMarch 25, 2024 | finance.yahoo.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoMarch 25, 2024 | globenewswire.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoMarch 16, 2024 | finance.yahoo.comAMRN Apr 2024 3.000 callSee More Headlines Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/04/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees275Year Founded1991Price Target and Rating Average Stock Price Target$1.08 High Stock Price Target$1.25 Low Stock Price Target$1.00 Potential Upside/Downside+19.0%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,110,000.00 Net Margins-18.96% Pretax Margin-17.24% Return on Equity-9.48% Return on Assets-6.34% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio1.80 Sales & Book Value Annual Sales$306.91 million Price / Sales1.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book0.68Miscellaneous Outstanding Shares410,670,000Free Float402,623,000Market Cap$373.71 million OptionableOptionable Beta1.96 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Patrick J. Holt (Age 51)President, CEO & Director Comp: $678.88kMr. Thomas Charles Reilly (Age 51)Executive VP, CFO & Global Head of HR Comp: $1.01MDr. Steven B. Ketchum Ph.D. (Age 59)Executive VP, President of Research & Development and Chief Scientific Officer Comp: $1.16MMr. Jonathan N. Provoost (Age 54)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $160.08kMr. Aaron D. Berg (Age 61)Executive VP & President of U.S. Comp: $1.26MMr. Jordan Zwick (Age 37)Senior VP of Corporate Business Development & Investor Relations Mr. Laurent AbuafPresident of Europe & Senior VPDr. Nabil AbadirChief Medical Officer of Global Medical AffairsDr. David Keenan Ph.D.Executive VP of Technical Operations & President of EuropeMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXRevance TherapeuticsNASDAQ:RVNCMereo BioPharma GroupNASDAQ:MREOEsperion TherapeuticsNASDAQ:ESPRMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 632,497 shares on 5/3/2024Ownership: 0.361%BNP Paribas Financial MarketsBought 476,996 shares on 5/1/2024Ownership: 0.227%Mirae Asset Global Investments Co. Ltd.Sold 57,817 shares on 5/1/2024Ownership: 0.016%China Universal Asset Management Co. Ltd.Bought 29,579 shares on 4/29/2024Ownership: 0.018%Newbridge Financial Services Group Inc.Bought 41,900 shares on 4/24/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions AMRN Stock Analysis - Frequently Asked Questions Should I buy or sell Amarin stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" AMRN shares. View AMRN analyst ratings or view top-rated stocks. What is Amarin's stock price target for 2024? 4 analysts have issued twelve-month price targets for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they anticipate the company's share price to reach $1.08 in the next twelve months. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts. How have AMRN shares performed in 2024? Amarin's stock was trading at $0.87 at the start of the year. Since then, AMRN shares have increased by 4.6% and is now trading at $0.91. View the best growth stocks for 2024 here. Are investors shorting Amarin? Amarin saw a decline in short interest in April. As of April 15th, there was short interest totaling 15,840,000 shares, a decline of 12.1% from the March 31st total of 18,020,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 9.4 days. View Amarin's Short Interest. When is Amarin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our AMRN earnings forecast. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) posted its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company earned $56.52 million during the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative net margin of 18.96% and a negative trailing twelve-month return on equity of 9.48%. During the same quarter last year, the company posted ($0.04) earnings per share. What is John Thero's approval rating as Amarin's CEO? 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX). Who are Amarin's major shareholders? Amarin's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.36%), BNP Paribas Financial Markets (0.23%), Simplicity Wealth LLC (0.11%), China Universal Asset Management Co. Ltd. (0.02%), Mirae Asset Global Investments Co. Ltd. (0.02%) and Westside Investment Management Inc. (0.02%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Amarin have any subsidiaries? The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.Read More This page (NASDAQ:AMRN) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe asset beating inflation by 4xColonial MetalsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
